Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PSMA PET Scan Clear all
Completed Phase 2 Interventional Results available

68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer

NCT04762888
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer

NCT04936334
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA-11 PET Scan
Diagnostic Test
Lead sponsor
Clinton Bahler
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

NCT03803475
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

NCT03503344
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Apalutamide, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

NCT06526299
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET-CT Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California • Sylmar, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

NCT06039371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 1 Interventional

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT06062745
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

NCT04402151
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

NCT05924672
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IVB Prostate Cancer AJCC v8
Interventions
Radium-223, PSMA Positron Emission Tomography (PET) Scan, Technetium Tc 99M Medronate
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Not applicable Interventional

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

NCT03368547
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer

NCT03429244
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA-11 PET-MRI
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery

NCT03515577
View directory record Official record
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

NCT06865768
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

NCT04946370
View directory record Official record
Conditions
Prostate Cancer
Interventions
225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed No phase listed Observational

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

NCT05527483
View directory record Official record
Conditions
Prostate Cancer
Interventions
[68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT
Drug · Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 17, 2026, 3:03 PM EDT
Not listed Not applicable Interventional

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

NCT05823402
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
SPECT/CT
Diagnostic Test
Lead sponsor
BAMF Health
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting No phase listed Observational

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

NCT07019844
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
West Los Angeles, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 1 Interventional

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Not yet recruiting Early Phase 1 Interventional

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

NCT07674771
View directory record Official record
Conditions
Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
Interventions
Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11, Adaptive stereotactive ablative radiotherapy (SABR)
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2Phase 3 Interventional

PSMA-PET to Guide Prostatectomy

NCT05381103
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA-PET and SOC MRI, SOC MRI
Diagnostic Test
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Completed No phase listed Observational

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Not yet recruiting Phase 1 Interventional

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07682649
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Other · Drug + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

NCT03949517
View directory record Official record
Conditions
Prostate Cancer
Interventions
68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan, PET/MRI
Drug · Device · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 17, 2026, 3:03 PM EDT